The Multi-center Study of Comprehensive Atrial Fibrillation Regurgitation and Recurrent Events Evaluation
Recruiting · NCT07085650 · Observational (researchers observe without assigning treatment) · Lead sponsor: First Hospital of China Medical University
View the official record on ClinicalTrials.gov →What this trial is about
Atrial fibrillation (AF) is the most common cardiac arrhythmia in the clinic and can lead to valve regurgitation and a poor prognosis. At present, atrial fibrillation ablation is one of the most effective means for the recurrence of atrial fibrillation in clinical practice, but the recurrence rate is high. Therefore, it is of great significance to find the predictors of relapse after atrial fibrillation ablation for clinical precision treatment. three-dimensional transesophageal ultrasound (3D-TEE) can comprehensively evaluate the valve regurgitation, flap ring changes, atrial or auricular thrombosis in patients with atrial fibrillation. It is also a necessary examination before atrial fibrillation ablation. Therefore, this study intends to combine 3D-TEE and three-dimensional transthoracic echocardiographic (3D-TTE) examination to evaluate the cardiac structure and function of patients. To comprehensively evaluate atrial fibrillation valve regurgitation and explore the predictors of recurrence after atrial fibrillation ablation.
Who can take part
Inclusion criteria
- Age ≥18 years old;
- Patients who came to the hospital with atrial fibrillation and intended to undergo ablation.
Exclusion criteria
- \- History of left atrial or left atrial appendix thrombus, new cerebral infarction and myocardial infarction (\< 6 months);
- Congenital heart disease, valvular heart disease, dilated heart disease, hypertrophic cardiomyopathy, pacemaker implantation, artificial valve replacement;
- hyperthyroidism, severe liver and kidney insufficiency;
- Proposed cardiac pacemaker implantation;
- Previous history of catheter ablation;
- The quality of three-dimensional transesophageal images was insufficient and could not be analyzed;
- refuse to sign the informed consent.
Where it is running
1 location listed.
- First Hospital of China Medical University - Shenyang, Liaoning, China